This is a long name for a condition called CIDP. It's a rare autoimmune disease that affects your nerves. It causes weakness, numbness, and tingling, often starting in your legs and arms. It's different from Guillain-Barré syndrome, which usually comes on much faster.
Every report comes from a Lived member, sent anonymously.
Have you tried IVIG for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune condition in which the immune system attacks the peripheral nerves, the nerves that run from the spinal cord to the arms, legs and the rest of the body, along with the nerve roots where they leave the spine. The damage falls mainly on myelin, the fatty coating that lets nerve signals travel quickly. When myelin is stripped away, signals slow down or get blocked, so muscles weaken and sensation changes. In its typical form, CIDP causes weakness on both sides of the body, both in the hands and feet and in the larger muscles around the hips and shoulders. People may notice trouble climbing stairs, getting up from a chair, gripping objects or keeping their balance, along with numbness, tingling, fatigue and sometimes pain. Reflexes such as the knee jerk are usually reduced or absent. Symptoms build over at least 8 weeks, either steadily or in episodes that improve and then return. CIDP is related to Guillain-Barré syndrome, another immune attack on the peripheral nerves. Guillain-Barré typically worsens over a few weeks, levels off and then slowly recovers, while CIDP keeps going beyond two months and usually does not improve without ongoing treatment. Some people have a variant form in which weakness is patchy and uneven, mostly in the hands or feet, or affects only movement or only sensation.
The exact cause of CIDP is unknown. It is considered an autoimmune disorder, meaning the body's own immune defenses turn against healthy nerve tissue, but why that happens in a particular person is not understood. Unlike Guillain-Barré syndrome, most people with CIDP cannot point to an infection or other event just before their symptoms began. CIDP can start at any age, including in childhood, but it most often begins around age 50, and men are affected about twice as often as women. Some evidence suggests diabetes may raise the risk, although diabetes also causes its own nerve damage that can be mistaken for CIDP. In a small group of people, the immune system makes specific antibodies against proteins at the junctions along the nerve (known as neurofascin-155 and contactin-1). Recognizing this form matters because it often responds poorly to the most common treatment and may need a different approach.
There is no single test for CIDP. A neurologist starts with the pattern and timing of symptoms, an examination of strength, sensation and reflexes, and a search for other causes of nerve damage. The key test is a nerve conduction study, usually done with electromyography (EMG). Small electrical pulses are applied to the skin over a nerve to measure how fast and how strongly signals travel. In CIDP, signals tend to be slowed or partly blocked in a pattern that points to damaged myelin. Results need to be read alongside the whole clinical picture, because inherited neuropathies and several other conditions can produce similar findings. Other tests can support the diagnosis. A lumbar puncture (spinal tap) may show a raised protein level in the spinal fluid without many white blood cells, although mild protein elevation is common in people who do not have CIDP. MRI or ultrasound can show swollen nerve roots or nerves. Blood tests look for look-alike causes such as diabetes, vitamin B12 deficiency, abnormal proteins made by blood cells, and certain infections. Getting the diagnosis right matters. In studies from several countries, roughly a third to half of people referred to specialty centers with a CIDP diagnosis turned out not to have it, which can mean years of treatment that does not help.
Treatment aims to stop the immune attack, restore strength and prevent lasting damage to the nerve fibers themselves, which is harder to reverse. People with only mild sensory symptoms and no loss of function are sometimes monitored rather than treated right away. Three treatments are standard first choices. Intravenous immunoglobulin (IVIg) is a concentrate of antibodies collected from donated blood plasma, given by infusion into a vein; Gamunex-C is one brand approved for CIDP. It has the strongest evidence from placebo-controlled trials, and people who respond usually continue infusions every few weeks. Common side effects include headache, nausea, rash and flu-like symptoms during or after an infusion; kidney problems and blood clots are rare but serious, so prescribers consider kidney health and clot risk. Corticosteroids such as prednisone, taken daily or as high-dose pulses once a month, appear to work about as well for typical CIDP, cost less and more often allow treatment to be stopped later. Their long-term downsides include weight gain, bone thinning, high blood sugar, mood changes and stomach ulcers, and their effect is usually judged after about three months. Plasma exchange uses a machine to remove antibody-containing plasma from the blood; it works, but benefits fade within weeks, so it is mainly used when the other two fail. The form of CIDP can shape the choice. IVIg is generally preferred when CIDP affects only the muscles, and patchy or one-sided forms tend to respond better to IVIg than to steroids. For long-term maintenance, immunoglobulin can also be given under the skin at home (subcutaneous immunoglobulin, such as Hizentra). Efgartigimod alfa with hyaluronidase (Vyvgart Hytrulo), approved for adults with CIDP in 2024, is a weekly injection under the skin that lowers the level of antibodies in the blood. It can raise the risk of infections, and live vaccines are not recommended while taking it. Other immune-suppressing medicines, and rituximab for the antibody-related form, are sometimes used when standard treatment fails, though their benefit has not been proven in large trials. Treating the effects of nerve damage is part of care too. Structured exercise programs, ideally supervised, have been linked to less fatigue and better day-to-day function, and medicines aimed at nerve pain can help when pain is a problem.
CIDP is usually a long-term condition, and most people improve with treatment, though how much varies. The course varies. Some people have a single period of worsening that settles with treatment, while others have relapses or need steady maintenance therapy for years. Up to about 30% eventually reach remission and can stop their first treatment. Finding the right treatment and dose often takes time. Care teams track progress with objective measures such as strength testing and standard disability scales, not only how a person feels, because doses are adjusted, and attempts to taper off treatment are judged, using these results. Ongoing infusions or injections become part of the routine, and some people learn to give subcutaneous treatment at home. About 10 to 20% of people continue to have problems despite treatment, sometimes because the diagnosis was not actually CIDP and sometimes because nerve fibers were permanently damaged before treatment began. Lasting numbness, weakness, fatigue or balance problems can affect walking, work and daily tasks, and physical therapy, mobility aids and practical adjustments help many people stay active and independent.
See a doctor, ideally with referral to a neurologist, if weakness, numbness, tingling or balance problems in the arms or legs have been building for weeks or keep coming back. If you already have CIDP, contact your care team if strength or sensation worsens, you start falling more often, treatment seems to wear off before the next dose, or side effects make treatment hard to continue. Get emergency care for trouble breathing or swallowing, or weakness that spreads quickly over hours to a few days. These are uncommon in CIDP, but rapid worsening can behave like Guillain-Barré syndrome, which can affect the breathing muscles.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is like, what's helped you, or ask the community a question.